A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
Year: 2015
Type: article
Study design: Clinical Trial
Institutions: Washington University in St. Louis, Rutgers, The State University of New Jersey, Hackensack University Medical Center, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston, Penn State Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Manchester, The Christie NHS Foundation Trust, Hôpital Saint-Louis, Université Paris Diderot, Asan Medical Center, University of Ulsan, Cleveland Clinic, Pfizer (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2013442295